Fostamatinib是美國里格爾制藥公司開發(fā)的一種口服的脾酪氨酸激酶抑制劑，為成年慢性免疫性血小板減少癥患者提供了一個(gè)全新的治療方案。其有效性已經(jīng)被臨床試驗(yàn)充分證實(shí)，于2018年5月由美國食品藥品管理局（FDA）批準(zhǔn)上市。概述了fostamatinib的基本性質(zhì)、合成路線、作用機(jī)制、藥動(dòng)學(xué)、藥物相互作用和臨床研究等內(nèi)容，以期為該類新藥研發(fā)以及合理用藥提供幫助。

Fostamatinib is an oral spleen tyrosine kinase inhibitor for the treatment of chronic immune thrombocytopenia developed by Rigel pharmaceutical company. Based on positive results in the phase clinical trials, the drug was recently approved by the US FDA in May, 2018 as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. In this review, the properties, synthetic route, mechanism, pharmacokinetics, drug interactions, and clinical trials of fostamatinib were reviewed to provide reference for new drug discovery and clinical application.